我國(guó)科學(xué)家找到腫瘤免疫治療潛在新途徑

Chinese scientists have discovered a protein called FBXO38 that affects the body's antitumor immunity, providing possible new insight into cancer immunotherapy.

近日，中國(guó)科學(xué)家發(fā)現(xiàn)了一種名為FBXO38、影響人體抗腫瘤免疫功能的蛋白質(zhì)，為癌癥免疫治療提供了可能的新視角。

In vitro studies by a group of researchers from the Chinese Academy of Sciences' Shanghai Institute of Biochemistry and Cell Biology have shown that a fairly low amount of FBXO38 leads to the accumulation of more PD-1 than the body requires. PD-1 is a molecule that helps keep the body's immune responses in check.

中國(guó)科學(xué)院生物化學(xué)與細(xì)胞生物學(xué)研究所的一組研究人員進(jìn)行的體外研究表明，相當(dāng)?shù)偷腇BXO38含量會(huì)導(dǎo)致超過(guò)人體所需的PD-1的積累。而PD-1是一種有助于抑制機(jī)體免疫反應(yīng)的分子。

Scientists found out many years ago that tumor cells often multiply and develop by finding ways to over-activate PD-1, which in turn impairs the body's ability to destroy tumor cells.

許多年前，科學(xué)家們就發(fā)現(xiàn)，腫瘤細(xì)胞常常通過(guò)尋找過(guò)于活躍的PD-1的方法來(lái)增殖和發(fā)展，而PD-1反過(guò)來(lái)又損害了人體破壞腫瘤細(xì)胞的能力。

The Chinese research paper, which took seven years to complete, was published on the website of British scientific journal Nature last Thursday.

這篇耗時(shí)七年完成的中國(guó)研究論文于上周四發(fā)表在英國(guó)科學(xué)雜志《自然》的網(wǎng)站上。

The scientists also found that an FDA-approved drug called IL-2, which is used to treat skin and kidney cancers, can boost the levels of FBXO38 in the tumor microenvironment to improve the effectiveness of killing cancer cells.

科學(xué)家們還發(fā)現(xiàn)，F(xiàn)DA批準(zhǔn)的一種名為IL-2的用于治療皮膚癌和腎癌的藥物，可以提高腫瘤微環(huán)境中FBXO38的水平，從而提高殺死癌細(xì)胞的有效性。

However, this drug has not been widely used for its obvious side effects, including vascular leakage and inflammation, the researchers said.

不過(guò)研究人員稱(chēng)，由于其副作用明顯，包括血管滲漏和炎癥，這種藥物還沒(méi)有被廣泛使用。

"One possible approach in clinical application might be optimizing the form of the drug and its dosage in the future and exploring its combined use with other therapies," said Xu Chenqi, the lead researcher.

首席研究員許琛琦表示：“在臨床應(yīng)用中，一種可能的方法可能是在未來(lái)優(yōu)化藥物的形式和劑量，并探索它與其他療法的聯(lián)合使用。”